Guanxinjing ameliorates coronary microvascular dysfunction in myocardial ischemia-reperfusion injury by alleviating inflammation and restoring endothelial function - Scorecard - MDSpire
Advertisement
Guanxinjing Enhances Coronary Microvascular Function in Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation and Improving Endothelial Activity
Clinical Scorecard: Guanxinjing Enhances Coronary Microvascular Function in Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation and Improving Endothelial Activity
At a Glance
Category
Detail
Condition
Coronary Microvascular Dysfunction (CMD)
Key Mechanisms
Reduction of inflammation and improvement of endothelial activity
Target Population
Patients with myocardial ischemia-reperfusion injury (MIRI)
Care Setting
Clinical treatment for coronary heart disease
Key Highlights
GXJC reduces myocardial infarct size and cardiomyocyte apoptosis.
Mechanistically, GXJC modulates the eNOS/NO/ET-1 axis.
GXJC suppresses vascular inflammation by inhibiting pro-inflammatory factors.
The TNF signaling pathway is identified as a key mechanism of GXJC.
GXJC shows potential for treating microvascular complications post-revascularization.
Guideline-Based Recommendations
Diagnosis
Evaluate coronary microvascular function in patients with MIRI.
Management
Consider GXJC as a therapeutic agent for MIRI-induced myocardial injury.
Monitoring & Follow-up
Monitor inflammatory markers and endothelial function in patients receiving GXJC.
Risks
Assess potential adverse effects associated with current therapies for CHD.
Patient & Prescribing Data
Patients with coronary heart disease and angina pectoris.
GXJC may offer a multi-target approach with improved safety profiles compared to existing therapies.
Clinical Best Practices
Utilize network pharmacology analysis to identify therapeutic targets.
Incorporate traditional Chinese medicine approaches in CMD management.
Conduct comprehensive evaluations of myocardial function post-treatment.
